Stock screener

TSHA

Conviction 100HealthcareScan · Thu, Jun 25, 2026
TSHA$6.21-10.52%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 4.73M
Mar 26Apr 14May 1May 19Jun 8Jun 25
Taysha Gene Therapies, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.tayshagtx.com
Price6.21
Change-10.52%
Gap-2.59%
Rel volume11.02×
Avg volume3.89M
Avg $ vol23.53M
SMA 205.94
SMA 506.13
SMA 2004.95
Price vs 50+1.37%
Price vs 200+25.39%
MA stackbullish
50/200 cross
Supertrendup · 5.75
RSI (14)53
MACD hist0.11
MACD crossbull · 7d
Stoch %K / %D53 / 78
ADX (14)22
+DI / −DI24 / 22
RSI divergence
MACD divergence
ATR %+6.92%
ADR %6.71%
52w high6.98
52w low2.31
From 52w high-11.03%
Above 52w low+168.83%
New 52w highNo
SqueezeOff
Bollinger width30.32%
%B0.65
Donchian pos52.91%
Donchian high7.06
Donchian low5.26
AVWAP (52w high)6.12
vs AVWAP high+1.52%
AVWAP (52w low)4.54
vs AVWAP low+36.70%
OBV trendFlat
Chaikin MF (20)-0.22
Today vs 20d11.02×
Avg vol (14d)4.73M
Avg vol (20d)3.89M
Avg $ vol (20d)23.53M
Market cap1.78B
RS 3m (vs SPY)+55.78%
RS 6m (vs SPY)+18.68%
RS line new highNo
Trend template8/8
Technical rank72.0
1 week+0.32%
1 month+11.09%
3 months+35.59%
6 months+5.97%
1 year+162.03%
YTD+18.29%
P/E-16.37
P/B8.42
P/S182.60
P/FCF-19.02
EPS-0.3400
Div yield
ROE-51.43%
ROA-36.29%
Debt/Eq0.23
Current14.04
EV/EBITDA
Gross margin
Net margin
Rev growth17.28%
EPS growth-22.06%
Price target12.50
Target upside101.29%
Analyst ratingBuy
Institutional99.13%
Ent. value1.56B
Revenue0
Net income-42.41M
Gross profit
Free cash flow-93.83M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out287.36M
Employees99
ListedThu, Sep 24, 2020
Free float228.89M
Float %83.6%
Short interest36.01M
Days to cover16.4d
Short volume45.7%
Squeeze score75 / 100
Next earnings
EPS forecast
Last EPS vs est−$0.12 vs −$0.10
Last surprise-20.0% miss
Setup gradeA+
Conviction100 / 100
Pattern quality
Tech rank72.0 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance6.65
Support5.21
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in TSHA

All disclosures →
No recent disclosed trades by Congress in TSHA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in TSHA · 8 buys · 1 sell

InsiderSideShares
Stalfort John A III
Director · Common Stock · 2026-06-01
Grant21.34K
Donenberg Phillip B.
Director · Stock Option (right to buy) · 2026-06-01
Grant42.67K
Stalfort John A III
Director · Common Stock · 2026-06-01
Other
Long Alison S
Director · Stock Option (right to buy) · 2026-06-01
Grant42.67K
Long Alison S
Director · Common Stock · 2026-06-01
Grant21.34K
Stalfort John A III
Director · Stock Option (right to buy) · 2026-06-01
Grant42.67K
Sepp-Lorenzino Laura
Director · Common Stock · 2026-06-01
Grant21.34K
Donenberg Phillip B.
Director · Common Stock · 2026-06-01
Grant21.34K
Sepp-Lorenzino Laura
Director · Stock Option (right to buy) · 2026-06-01
Grant42.67K
Nagendran Sukumar
President and Head of R&D · Common Stock · 2026-04-10
Sell200K

SEC filings

EDGAR filings in TSHA · 5 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.